http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Mon, 15 Jun 2026 17:27:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Whitehawk+Therapeutics%2C+++For%3A+Jun+12++Filed+by%3A+Zhao+Baiteng/26648723.html si-local-file:///var/storage/secattach/20260615/26648723.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Whitehawk+Therapeutics%2C+++For%3A+Jun+12++Filed+by%3A+Zhao+Baiteng/26648723.html Mon, 15 Jun 2026 17:27:00 -0400 O.37125755 WHWK http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Whitehawk+Therapeutics%2C+++For%3A+Jun+12++Filed+by%3A+Zhao+Baiteng/26648723.html si-local-file:///var/storage/secattach/20260615/26648723.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Whitehawk+Therapeutics%2C+++For%3A+Jun+12++Filed+by%3A+Zhao+Baiteng/26648723.html Mon, 15 Jun 2026 17:27:00 -0400 O.37125755 WHWK http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Whitehawk+Therapeutics%2C+++For%3A+Jun+12++Filed+by%3A+Reeve+Emma/26648712.html si-local-file:///var/storage/secattach/20260615/26648712.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Whitehawk+Therapeutics%2C+++For%3A+Jun+12++Filed+by%3A+Reeve+Emma/26648712.html Mon, 15 Jun 2026 17:26:00 -0400 O.37125755 WHWK http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Whitehawk+Therapeutics%2C+++For%3A+Jun+12++Filed+by%3A+Reeve+Emma/26648712.html si-local-file:///var/storage/secattach/20260615/26648712.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Whitehawk+Therapeutics%2C+++For%3A+Jun+12++Filed+by%3A+Reeve+Emma/26648712.html Mon, 15 Jun 2026 17:26:00 -0400 O.37125755 WHWK http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Whitehawk+Therapeutics%2C+++For%3A+Jun+12++Filed+by%3A+Maroun+Richard+E/26648691.html si-local-file:///var/storage/secattach/20260615/26648691.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Whitehawk+Therapeutics%2C+++For%3A+Jun+12++Filed+by%3A+Maroun+Richard+E/26648691.html Mon, 15 Jun 2026 17:24:00 -0400 O.37125755 WHWK http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Whitehawk+Therapeutics%2C+++For%3A+Jun+12++Filed+by%3A+Maroun+Richard+E/26648691.html si-local-file:///var/storage/secattach/20260615/26648691.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Whitehawk+Therapeutics%2C+++For%3A+Jun+12++Filed+by%3A+Maroun+Richard+E/26648691.html Mon, 15 Jun 2026 17:24:00 -0400 O.37125755 WHWK http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Whitehawk+Therapeutics%2C+++For%3A+Jun+12++Filed+by%3A+Hirmand+Mohammad/26648672.html si-local-file:///var/storage/secattach/20260615/26648672.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Whitehawk+Therapeutics%2C+++For%3A+Jun+12++Filed+by%3A+Hirmand+Mohammad/26648672.html Mon, 15 Jun 2026 17:23:00 -0400 O.37125755 WHWK http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Whitehawk+Therapeutics%2C+++For%3A+Jun+12++Filed+by%3A+Hirmand+Mohammad/26648672.html si-local-file:///var/storage/secattach/20260615/26648672.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Whitehawk+Therapeutics%2C+++For%3A+Jun+12++Filed+by%3A+Hirmand+Mohammad/26648672.html Mon, 15 Jun 2026 17:23:00 -0400 O.37125755 WHWK http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Whitehawk+Therapeutics%2C+++For%3A+Jun+12++Filed+by%3A+Castelein+Caley/26648656.html si-local-file:///var/storage/secattach/20260615/26648656.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Whitehawk+Therapeutics%2C+++For%3A+Jun+12++Filed+by%3A+Castelein+Caley/26648656.html Mon, 15 Jun 2026 17:22:00 -0400 O.37125755 WHWK http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Whitehawk+Therapeutics%2C+++For%3A+Jun+12++Filed+by%3A+Castelein+Caley/26648656.html si-local-file:///var/storage/secattach/20260615/26648656.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Whitehawk+Therapeutics%2C+++For%3A+Jun+12++Filed+by%3A+Castelein+Caley/26648656.html Mon, 15 Jun 2026 17:22:00 -0400 O.37125755 WHWK http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Whitehawk+Therapeutics%2C+++For%3A+Jun+12++Filed+by%3A+Desai+Neil/26648663.html si-local-file:///var/storage/secattach/20260615/26648663.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Whitehawk+Therapeutics%2C+++For%3A+Jun+12++Filed+by%3A+Desai+Neil/26648663.html Mon, 15 Jun 2026 17:22:00 -0400 O.37125755 WHWK http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Whitehawk+Therapeutics%2C+++For%3A+Jun+12++Filed+by%3A+Desai+Neil/26648663.html si-local-file:///var/storage/secattach/20260615/26648663.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Whitehawk+Therapeutics%2C+++For%3A+Jun+12++Filed+by%3A+Desai+Neil/26648663.html Mon, 15 Jun 2026 17:22:00 -0400 O.37125755 WHWK http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Whitehawk+Therapeutics%2C+++For%3A+Jun+12++Filed+by%3A+Avoro+Ventures+LLC/26648624.html si-local-file:///var/storage/secattach/20260615/26648624.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Whitehawk+Therapeutics%2C+++For%3A+Jun+12++Filed+by%3A+Avoro+Ventures+LLC/26648624.html Mon, 15 Jun 2026 17:19:00 -0400 O.37125755 WHWK http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Whitehawk+Therapeutics%2C+++For%3A+Jun+12++Filed+by%3A+Avoro+Ventures+LLC/26648624.html si-local-file:///var/storage/secattach/20260615/26648624.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Whitehawk+Therapeutics%2C+++For%3A+Jun+12++Filed+by%3A+Avoro+Ventures+LLC/26648624.html Mon, 15 Jun 2026 17:19:00 -0400 O.37125755 WHWK http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Whitehawk+Therapeutics%2C+++For%3A+Jun+11/26641102.html si-local-file:///var/storage/secattach/20260612/26641102.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Whitehawk+Therapeutics%2C+++For%3A+Jun+11/26641102.html Fri, 12 Jun 2026 16:19:00 -0400 O.37125755 WHWK http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Whitehawk+Therapeutics%2C+++For%3A+Jun+11/26641102.html si-local-file:///var/storage/secattach/20260612/26641102.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Whitehawk+Therapeutics%2C+++For%3A+Jun+11/26641102.html Fri, 12 Jun 2026 16:19:00 -0400 O.37125755 WHWK http://www.streetinsider.com/SEC+Filings/Form++EFFECT+++++Whitehawk+Therapeutics%2C++++++++++++++/26626135.html si-local-file:///var/storage/secattach/20260610/26626135.html http://www.streetinsider.com/SEC+Filings/Form++EFFECT+++++Whitehawk+Therapeutics%2C++++++++++++++/26626135.html Wed, 10 Jun 2026 06:03:00 -0400 O.37125755 WHWK http://www.streetinsider.com/SEC+Filings/Form++EFFECT+++++Whitehawk+Therapeutics%2C++++++++++++++/26626135.html si-local-file:///var/storage/secattach/20260610/26626135.html http://www.streetinsider.com/SEC+Filings/Form++EFFECT+++++Whitehawk+Therapeutics%2C++++++++++++++/26626135.html Wed, 10 Jun 2026 06:03:00 -0400 O.37125755 WHWK http://www.streetinsider.com/Press+Releases/Whitehawk+Therapeutics+Presents+Real%E2%80%91World+Analysis+Confirming+SEZ6+as+a+Highly+Expressed%2C+Clinically+Relevant+Target+for+SCLC+and+Other+Neuroendocrine+Tumors+at+ASCO+2026/26577263.html <div class="xn-content"> <p class="prntac"><i>SEZ6 expression exceeds that of approved and emerging ADC targets in SCLC </i> </p><p class="prntac"><i>SEZ6 expression is positively correlated with DLL3 expression across neuroendocrine carcinomas, indicating potential for combination </i></p><p class="prntac"><i>Findings support Whitehawk's development of SEZ6-directed ADC, HWK-206, with an IND submission expected mid-2026</i></p><p><span class="legendSpanClass"><location value="LU/us.nj.morown" idsrc="xmltag.org" >MORRISTOWN, N.J.</location></span>, <span class="legendSpanClass"><chron>May 30, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:WHWK" idsrc="xmltag.org" >Whitehawk Therapeutics</span>, Inc. (Nasdaq: WHWK), a clinical-stage oncology therapeutics company applying advanced technologies to established tumor biology to efficiently deliver improved antibody drug conjugate (ADC) cancer treatments, today announced the presentation of a real world analysis supporting the therapeutic potential of targeting seizure http://www.streetinsider.com/Press+Releases/Whitehawk+Therapeutics+Presents+Real%E2%80%91World+Analysis+Confirming+SEZ6+as+a+Highly+Expressed%2C+Clinically+Relevant+Target+for+SCLC+and+Other+Neuroendocrine+Tumors+at+ASCO+2026/26577263.html Sat, 30 May 2026 14:30:00 -0400 A.22710740 A.50216726 O.20161007 O.21612337 O.37125755 WHWK http://www.streetinsider.com/Press+Releases/Whitehawk+Therapeutics+Presents+Real%E2%80%91World+Analysis+Confirming+SEZ6+as+a+Highly+Expressed%2C+Clinically+Relevant+Target+for+SCLC+and+Other+Neuroendocrine+Tumors+at+ASCO+2026/26577263.html <div class="xn-content"> <p class="prntac"><i>SEZ6 expression exceeds that of approved and emerging ADC targets in SCLC </i> </p><p class="prntac"><i>SEZ6 expression is positively correlated with DLL3 expression across neuroendocrine carcinomas, indicating potential for combination </i></p><p class="prntac"><i>Findings support Whitehawk's development of SEZ6-directed ADC, HWK-206, with an IND submission expected mid-2026</i></p><p><span class="legendSpanClass"><location value="LU/us.nj.morown" idsrc="xmltag.org" >MORRISTOWN, N.J.</location></span>, <span class="legendSpanClass"><chron>May 30, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:WHWK" idsrc="xmltag.org" >Whitehawk Therapeutics</span>, Inc. (Nasdaq: WHWK), a clinical-stage oncology therapeutics company applying advanced technologies to established tumor biology to efficiently deliver improved antibody drug conjugate (ADC) cancer treatments, today announced the presentation of a real world analysis supporting the therapeutic potential of targeting seizure http://www.streetinsider.com/Press+Releases/Whitehawk+Therapeutics+Presents+Real%E2%80%91World+Analysis+Confirming+SEZ6+as+a+Highly+Expressed%2C+Clinically+Relevant+Target+for+SCLC+and+Other+Neuroendocrine+Tumors+at+ASCO+2026/26577263.html Sat, 30 May 2026 14:30:00 -0400 A.22710740 A.50216726 O.20161007 O.21612337 O.37125755 WHWK http://www.streetinsider.com/Press+Releases/Whitehawk+Therapeutics+Presents+Real%E2%80%91World+Analysis+Confirming+SEZ6+as+a+Highly+Expressed%2C+Clinically+Relevant+Target+for+SCLC+and+Other+Neuroendocrine+Tumors+at+ASCO+2026/26577263.html <div class="xn-content"> <p class="prntac"><i>SEZ6 expression exceeds that of approved and emerging ADC targets in SCLC </i> </p><p class="prntac"><i>SEZ6 expression is positively correlated with DLL3 expression across neuroendocrine carcinomas, indicating potential for combination </i></p><p class="prntac"><i>Findings support Whitehawk's development of SEZ6-directed ADC, HWK-206, with an IND submission expected mid-2026</i></p><p><span class="legendSpanClass"><location value="LU/us.nj.morown" idsrc="xmltag.org" >MORRISTOWN, N.J.</location></span>, <span class="legendSpanClass"><chron>May 30, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:WHWK" idsrc="xmltag.org" >Whitehawk Therapeutics</span>, Inc. (Nasdaq: WHWK), a clinical-stage oncology therapeutics company applying advanced technologies to established tumor biology to efficiently deliver improved antibody drug conjugate (ADC) cancer treatments, today announced the presentation of a real world analysis supporting the therapeutic potential of targeting seizure http://www.streetinsider.com/Press+Releases/Whitehawk+Therapeutics+Presents+Real%E2%80%91World+Analysis+Confirming+SEZ6+as+a+Highly+Expressed%2C+Clinically+Relevant+Target+for+SCLC+and+Other+Neuroendocrine+Tumors+at+ASCO+2026/26577263.html Sat, 30 May 2026 14:30:00 -0400 A.22710740 A.50216726 O.20161007 O.21612337 O.37125755 WHWK http://www.streetinsider.com/Press+Releases/Whitehawk+Therapeutics+Presents+Real%E2%80%91World+Analysis+Confirming+SEZ6+as+a+Highly+Expressed%2C+Clinically+Relevant+Target+for+SCLC+and+Other+Neuroendocrine+Tumors+at+ASCO+2026/26577263.html <div class="xn-content"> <p class="prntac"><i>SEZ6 expression exceeds that of approved and emerging ADC targets in SCLC </i> </p><p class="prntac"><i>SEZ6 expression is positively correlated with DLL3 expression across neuroendocrine carcinomas, indicating potential for combination </i></p><p class="prntac"><i>Findings support Whitehawk's development of SEZ6-directed ADC, HWK-206, with an IND submission expected mid-2026</i></p><p><span class="legendSpanClass"><location value="LU/us.nj.morown" idsrc="xmltag.org" >MORRISTOWN, N.J.</location></span>, <span class="legendSpanClass"><chron>May 30, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:WHWK" idsrc="xmltag.org" >Whitehawk Therapeutics</span>, Inc. (Nasdaq: WHWK), a clinical-stage oncology therapeutics company applying advanced technologies to established tumor biology to efficiently deliver improved antibody drug conjugate (ADC) cancer treatments, today announced the presentation of a real world analysis supporting the therapeutic potential of targeting seizure http://www.streetinsider.com/Press+Releases/Whitehawk+Therapeutics+Presents+Real%E2%80%91World+Analysis+Confirming+SEZ6+as+a+Highly+Expressed%2C+Clinically+Relevant+Target+for+SCLC+and+Other+Neuroendocrine+Tumors+at+ASCO+2026/26577263.html Sat, 30 May 2026 14:30:00 -0400 A.22710740 A.50216726 O.20161007 O.21612337 O.37125755 WHWK http://www.streetinsider.com/Press+Releases/Whitehawk+Therapeutics+Presents+Real%E2%80%91World+Analysis+Confirming+SEZ6+as+a+Highly+Expressed%2C+Clinically+Relevant+Target+for+SCLC+and+Other+Neuroendocrine+Tumors+at+ASCO+2026/26577263.html <div class="xn-content"> <p class="prntac"><i>SEZ6 expression exceeds that of approved and emerging ADC targets in SCLC </i> </p><p class="prntac"><i>SEZ6 expression is positively correlated with DLL3 expression across neuroendocrine carcinomas, indicating potential for combination </i></p><p class="prntac"><i>Findings support Whitehawk's development of SEZ6-directed ADC, HWK-206, with an IND submission expected mid-2026</i></p><p><span class="legendSpanClass"><location value="LU/us.nj.morown" idsrc="xmltag.org" >MORRISTOWN, N.J.</location></span>, <span class="legendSpanClass"><chron>May 30, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:WHWK" idsrc="xmltag.org" >Whitehawk Therapeutics</span>, Inc. (Nasdaq: WHWK), a clinical-stage oncology therapeutics company applying advanced technologies to established tumor biology to efficiently deliver improved antibody drug conjugate (ADC) cancer treatments, today announced the presentation of a real world analysis supporting the therapeutic potential of targeting seizure http://www.streetinsider.com/Press+Releases/Whitehawk+Therapeutics+Presents+Real%E2%80%91World+Analysis+Confirming+SEZ6+as+a+Highly+Expressed%2C+Clinically+Relevant+Target+for+SCLC+and+Other+Neuroendocrine+Tumors+at+ASCO+2026/26577263.html Sat, 30 May 2026 14:30:00 -0400 A.22710740 A.50216726 O.20161007 O.21612337 O.37125755 WHWK http://www.streetinsider.com/Press+Releases/Whitehawk+Therapeutics+Presents+Real%E2%80%91World+Analysis+Confirming+SEZ6+as+a+Highly+Expressed%2C+Clinically+Relevant+Target+for+SCLC+and+Other+Neuroendocrine+Tumors+at+ASCO+2026/26577263.html <div class="xn-content"> <p class="prntac"><i>SEZ6 expression exceeds that of approved and emerging ADC targets in SCLC </i> </p><p class="prntac"><i>SEZ6 expression is positively correlated with DLL3 expression across neuroendocrine carcinomas, indicating potential for combination </i></p><p class="prntac"><i>Findings support Whitehawk's development of SEZ6-directed ADC, HWK-206, with an IND submission expected mid-2026</i></p><p><span class="legendSpanClass"><location value="LU/us.nj.morown" idsrc="xmltag.org" >MORRISTOWN, N.J.</location></span>, <span class="legendSpanClass"><chron>May 30, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:WHWK" idsrc="xmltag.org" >Whitehawk Therapeutics</span>, Inc. (Nasdaq: WHWK), a clinical-stage oncology therapeutics company applying advanced technologies to established tumor biology to efficiently deliver improved antibody drug conjugate (ADC) cancer treatments, today announced the presentation of a real world analysis supporting the therapeutic potential of targeting seizure http://www.streetinsider.com/Press+Releases/Whitehawk+Therapeutics+Presents+Real%E2%80%91World+Analysis+Confirming+SEZ6+as+a+Highly+Expressed%2C+Clinically+Relevant+Target+for+SCLC+and+Other+Neuroendocrine+Tumors+at+ASCO+2026/26577263.html Sat, 30 May 2026 14:30:00 -0400 A.22710740 A.50216726 O.20161007 O.21612337 O.37125755 WHWK http://www.streetinsider.com/PRNewswire/Whitehawk+Therapeutics+Presents+Real%E2%80%91World+Analysis+Confirming+SEZ6+as+a+Highly+Expressed%2C+Clinically+Relevant+Target+for+SCLC+and+Other+Neuroendocrine+Tumors+at+ASCO+2026/26577263.html <div class="xn-content"> <p class="prntac"><i>SEZ6 expression exceeds that of approved and emerging ADC targets in SCLC </i> </p><p class="prntac"><i>SEZ6 expression is positively correlated with DLL3 expression across neuroendocrine carcinomas, indicating potential for combination </i></p><p class="prntac"><i>Findings support Whitehawk's development of SEZ6-directed ADC, HWK-206, with an IND submission expected mid-2026</i></p><p><span class="legendSpanClass"><location value="LU/us.nj.morown" idsrc="xmltag.org" >MORRISTOWN, N.J.</location></span>, <span class="legendSpanClass"><chron>May 30, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:WHWK" idsrc="xmltag.org" >Whitehawk Therapeutics</span>, Inc. (Nasdaq: WHWK), a clinical-stage oncology therapeutics company applying advanced technologies to established tumor biology to efficiently deliver improved antibody drug conjugate (ADC) cancer treatments, today announced the presentation of a real world analysis supporting the therapeutic potential of targeting seizure http://www.streetinsider.com/PRNewswire/Whitehawk+Therapeutics+Presents+Real%E2%80%91World+Analysis+Confirming+SEZ6+as+a+Highly+Expressed%2C+Clinically+Relevant+Target+for+SCLC+and+Other+Neuroendocrine+Tumors+at+ASCO+2026/26577263.html Sat, 30 May 2026 14:30:00 -0400 A.22710740 A.50216726 O.20161007 O.21612337 O.37125755 WHWK